Canaccord Genuity Initiates Coverage of Natera With Buy Rating

Jan 06, 2017

|

NEW YORK (GenomeWeb) – Canaccord Genuity today initiated coverage of molecular diagnostics company Natera with a Buy rating. It set a price target of $18.00 for the company's stock.

The San Carlos, California-based company markets a sequencing-based noninvasive prenatal test and is developing cancer products that analyze circulating tumor DNA.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Menu

Canaccord Genuity Initiates Coverage of Natera With Buy Rating

To read the full story....

Breaking News

Exact Sciences, Express Gene, Avera Institute Get FDA EUAs for Coronavirus Tests

AstraZeneca, ArcherDx Partner on Minimal Residual Disease Monitoring for Lung Cancer Drug Trials

BioCore, SolGent, Seasun Get FDA Emergency Use Authorizations for Coronavirus Tests

P23 Labs Receives FDA Emergency Use Authorization for SARS-CoV-2 Test

Genedrive Receives CE Mark for SARS-CoV-2 PCR Kit

Local Coverage Determinations Roundup: Aspira Labs, Fujirebio Diagnostics

Featured White Papers

COVID-19 Testing, Treatment and Future Outlook

What's Popular?

Head-to-Head Comparisons of Commercial SARS-CoV-2 MDx Tests Point to Few Differences in Accuracy

CMS Sets Reimbursement Rates for SARS-CoV-2 Serology Tests

BioCore, SolGent, Seasun Get FDA Emergency Use Authorizations for Coronavirus Tests

Genedrive Receives CE Mark for SARS-CoV-2 PCR Kit

BioMérieux's BioFire Pneumonia Panel Could Improve Care, Find Secondary Infection in COVID-19 Cases

Sponsorships